Dr Andrew Hill presenting at HIV Glasgow 2022. Image by Alan Donaldson Photography.
Dr Andrew Hill presenting at HIV Glasgow 2022. Image by Alan Donaldson Photography.Dolutegravir-based treatment is significantly more likely to result in re-suppression of HIV after viral rebound than treatment containing efavirenz, a meta-analysis of four large clinical trials has reported.
The findings were presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) by Dr Andrew Hill of Liverpool University.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
Infectious Disease Advisor: Dolutegravir plus lamivudine maintains HIV-1 suppression without HBV reactivation
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.